Skip to content
TrialScanner

NCT04596319

Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis

Phase 1/Phase 2CompletedARMPLead

Registry record

Lead sponsor
Armata Pharmaceuticals, Inc.
Conditions
Cystic Fibrosis; Pseudomonas Aeruginosa; Pseudomonas; Lung Infection; Lung Infection Pseudomonal
Primary completion
Dec 14, 2022Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04596319 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04596319: Ph 1/2 Study Evaluating... | TrialScanner